Intrathecal alemtuzumab: a potential treatment of refractory leptomeningeal T-cell prolymphocytic leukemia

Fares Alsawah, Lydia L. Benitez, Sarah M. Choi, Bernard L. Marini, Anthony J. Perissinotti, Amy J. Skyles, Patrick W. Burke, Kristen Pettit, Ashley Crouch, Heather Fox,

Blood Advances · 2019 · 10 citations · 10 references

DOIFull text

Open access

Concepts

Abstract

Key Points This is the first report of successful treatment of therapy-resistant leptomeningeal T-PLL with intrathecal alemtuzumab. Intrathecal alemtuzumab is a potentially safe and efficacious therapeutic alternative for treatment of leptomeningeal T-PLL.

References

10